Document Detail

Variceal bleeding: pharmacological therapy.
MedLine Citation:
PMID:  15920322     Owner:  NLM     Status:  MEDLINE    
The complications of portal hypertension are totally prevented if hepatic venous pressure gradient is decreased below 12 mm Hg. Besides, if this target is not achieved, a 20% decrease in portal pressure from baseline levels offers an almost total protection from variceal bleeding. This sets the rationale for drug therapy to reduce portal pressure in portal hypertension. Pharmacological therapy to decrease portal pressure includes vasoconstrictors to decrease portal blood inflow, vasodilators to decrease hepatic resistance, and combination therapy. Oral agents, such as beta-adrenergic blockers and organic nitrates, are used for long-term prevention of variceal bleeding, while parenteral agents, such as somatostatin (and analogues) and terlipressin, are used for the treatment of acute variceal bleeding.
Jaime Bosch; Juan G Abraldes
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Digestive diseases (Basel, Switzerland)     Volume:  23     ISSN:  0257-2753     ISO Abbreviation:  Dig Dis     Publication Date:  2005  
Date Detail:
Created Date:  2005-05-27     Completed Date:  2005-08-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701186     Medline TA:  Dig Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  18-29     Citation Subset:  IM    
Copyright Information:
2005 S. Karger AG, Basel
Hepatic Hemodynamics Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Adrenergic alpha-Antagonists / therapeutic use
Hemorrhage / drug therapy*,  etiology*
Hypertension, Portal / complications*,  drug therapy*
Liver / blood supply
Nitrates / therapeutic use
Regional Blood Flow
Varicose Veins / complications*
Vasoconstrictor Agents / therapeutic use*
Vasodilator Agents / therapeutic use*
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Nitrates; 0/Vasoconstrictor Agents; 0/Vasodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of endoscopy in portal hypertension.
Next Document:  Refractory ascites.